Kathryn Wheeler, PharmD, BCPS
Kathryn Wheeler, PharmD, BCPS, is assistant clinical professor of pharmacy practice, University of Connecticut School of Pharmacy, Storrs, Conn.
New dosage form for migraine treatment
FDA approved Onzetra Xsail (Avanir Pharmaceuticals Inc.)— a fast-acting, low-dose sumatriptan dry powder formulation for the acute treatment of migraine with or without aura in adults.
Long-term safety of glycopyrrolate: A randomized study of COPD patients
Glycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.
Dual therapy strategies for COPD: The scientific rationale for LAMA & LABA
There is a growing group of LAMA/LABA combination therapies in development. Investigations into the risks and benefits of LAMA/LABA therapy have demonstrated benefits.
COPD and pharmacotherapy for smoking cessation at the VA: Study
Use of tobacco-cessation therapy was low. The study found several negative factors — and two positive predictors.
Umeclidinium triple therapy for patients with COPD: Two studies
Both studies demonstrated statistical improvements in trough FEV1 at day 85.
New drug approved for gout maintenance therapy
Lesinurad is indicated as an adjunctive treatment when a xanthine oxidase inhibitor alone is not producing desired results.
New adjunctive medication for eosinophilic asthma
FDA has approved mepolizumab for adjunctive maintenance treatment of severe asthma in patients 12 years of age and older with markers of eosinophilic asthma.
Flibanserin: Risk potential vs. possible benefit
Because of concerns about adverse effects, training through the Addyi REMS program is required for prescribers and pharmacies that want to participate in the medication use process for this drug.
FDA approves new Pradaxa reversal agent
Patients taking Pradaxa had no option for anticoagulation reversal; it was this unmet medical need that caused FDA to grant idarucizumab accelerated approval.
New first-in-class drug therapy for heart failure
In April 2015, FDA approved Ivabradine to reduce the risk of hospitalizations due to worsening heart failure in indicated patients.